Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ADI-100
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aditxt’s Adimune Completes Preclinical Studies for Immune Modulation Platform
Details : ADI-100 is designed to reprogram, downregulate pro-inflammatory cytokines while upregulating anti-inflammatory cytokines in an antigen-specific manner. it is being investigated for Type 1 Diabetes.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
December 12, 2024
Lead Product(s) : ADI-100
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable